Symbotic Inc. SYM is scheduled to release second-quarter fiscal 2025 results on May 7, after market close. The company surpassed the Zacks Consensus Estimate in three of the four trailing quarters and missed once, delivering an average earnings surprise of 181.3%. Symbotic Inc. Price and EPS Surprise Symbotic Inc. price-eps-surprise | Symbotic Inc. Quote Symbiotic’s Q2 Expectations The Zacks Consensus Estimate for SYM’s revenues is pegged at $517.9 million, indicating a 22.1% rise from the year-ago quarter’s actual. Solid progress across systems in the deployment process and recurring revenues from software and operation services are anticipated to have fueled the top line. The consensus estimate for systems revenues is pegged at $486.5 million, up 31.2% year over year. The Zacks Consensus Estimate for software maintenance and support revenues is pegged at $5.7 million, implying a more than 100% surge from the year-ago quarter’s actual. The consensus mark for operation services revenues is pegged at $25.5 million, suggesting a 26.8% increase on a year-over-year basis. The consensus estimate for earnings is pegged at 5 cents per share, indicating a 77.3% fall from the year-ago quarter’s actual. Labor price inflation, increasing the cost of goods sold, is expected to have hurt the bottom line. What Our Model Says About SYM Our proven model does not predict an earnings beat for Symbiotic this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here. You can uncover the best stocks before they are reported with our Earnings ESP Filter. SYM has an Earnings ESP of 0.00% and a Zacks Rank of 3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. Earnings Snapshot Equifax Inc. EFX reported impressive first-quarter 2025 results. EFX’s adjusted earnings were $1.53 per share, outpacing the Zacks Consensus Estimate by 9.3% and increasing 2% from the year-ago quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Total revenues of $1.4 billion surpassed the consensus estimate by 1.9% and grew 3.6% on a year-over-year basis. S&P Global Inc. SPGI posted impressive first-quarter 2025 results. SPGI’s adjusted earnings per share of $4.37 surpassed the Zacks Consensus Estimate by 3.6% and rose 9% year over year. Revenues of $3.8 billion beat the consensus estimate by 2% and grew 8.3% year over year. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues Equifax, Inc. (EFX):Free Stock Analysis Report S&P Global Inc. (SPGI):Free Stock Analysis Report Symbotic Inc. (SYM):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Symbiotic Gears Up to Report Q2 Earnings: What's in the Offing?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...